Anti-HBME-1 has been demonstrated to label mesothelial cells, both benign and malignant (malignant mesothelioma) and thus has been used in distinguishing mesothelioma from adenocarcinomas of various origins. More recently this antibody has been used to distinguish Thyroid carcinomas (both Follicular and Papillary) from benign thyroid lesions.
Anti-HBME-1 has been demonstrated to label mesothelial cells, both benign and malignant (malignant mesothelioma) and thus has been used in distinguishing mesothelioma from adenocarcinomas of various origins. More recently this antibody has been used to distinguish Thyroid carcinomas (both Follicular and Papillary) from benign thyroid lesions.
http://www.cellmarque.com/Cell Marque
Anti-HBME-1 has been demonstrated to label mesothelial cells, both benign and malignant (malignant mesothelioma) and thus has been used in distinguishing mesothelioma from adenocarcinomas of various origins. More recently this antibody has been used to distinguish Thyroid carcinomas (both Follicular and Papillary) from benign thyroid lesions.
